AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions of claims in the application.

Claim 1. (Withdrawn): A nuclear transfer promoter for Cdc42 protein comprising an isoprenoid

synthesis inhibitor and/or a geranylgeranyl transferase inhibitor.

Claim 2. (Withdrawn): The nuclear transfer promoter for Cdc42 protein according to claim 1,

wherein the isoprenoid synthesis inhibitor is an HMG-CoA synthase inhibitor, an HMG-CoA

reductase inhibitor, an AMPK activator or a farnesylpyrophosphoric acid synthase preparation.

Claim 3. (Withdrawn): The nuclear transfer promoter for Cdc42 protein according to claim 2,

wherein the HMG-CoA reductase inhibitor is pitavastatin.

Claim 4. (Withdrawn): Use, as a nuclear transfer promoter for Cdc42 protein, of an isoprenoid

synthesis inhibitor and/or a geranylgeranyl transferase inhibitor.

Claim 5. (Withdrawn): The use as a nuclear transfer promoter for Cdc42 protein according to

claim 4, wherein the isoprenoid synthesis inhibitor is an HMG-CoA synthase inhibitor, an

HMG-CoA reductase inhibitor, an AMPK activator or a farnesylpyrophosphoric acid synthase

preparation.

Claim 6. (Withdrawn): The use as a nuclear transfer promoter for Cdc42 protein according to claim 5, wherein the HMG-CoA reductase inhibitor is pitavastatin.

Claim 7. (Currently Amended): A method of promoting the transfer of Cdc42 protein from outside a nucleus of a cell into [[a]] the nucleus of the cell, comprising the step of: which comprises

administering an isoprenoid synthesis inhibitor and/or a geranylgeranyl transferase inhibitor to [[a]] the cell, and

transferring Cdc42 protein from outside the nucleus of the cell into the nucleus of the cell.

Claim 8. (Original): The method according to claim 7, wherein the isoprenoid synthesis inhibitor is an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, an AMPK activator or a farnesylpyrophosphoric acid synthase preparation.

Claim 9. (Original): The method according to claim 8, wherein the HMG-CoA reductase inhibitor is pitavastatin.

Claim 10. (Withdrawn): A pharmaceutical composition for vascular treatment, comprising the nuclear transfer promoter for Cdc42 protein according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier.

Application No.: 10/590,492

Response

Attorney Docket No.: 032217A

Claim 11. (Withdrawn): Use of the nuclear transfer promoter for Cdc42 protein according to any

one of claims 1 to 3 in producing a blood vessel remedy.

Claim 12. (Withdrawn): A therapeutic/prevention method for vascular disorders, which

comprises administering the nuclear transfer promoter for Cdc42 protein according to any one of

claims 1 to 3 in an effective amount for therapy/prevention to a patient in need of

therapy/prevention of vascular disorders.

Claim 13. (Withdrawn): A method of screening a blood vessel remedy, which comprises adding

a test substance to a Cdc42 protein-expressing cell and measuring the transfer of Cdc42 protein

into the nucleus.

Claim 14. (Withdrawn): The screening method according to claim 13, wherein Cdc42 protein is

in the form of a fusion protein with a fluorescent protein.

Claim 15. (Withdrawn): The screening method according to claim 13 or 14, wherein the transfer

of Cdc42 protein into the nucleus is measured by observation with fluorescence.

- 4 -